GPC1 and neoplasm: Utilizing an immune lipoplex nanoparticle (ILN) biochip assay, these findings show that combined glypican 1 (GPC1) mRNA expression in exosomes and GPC1 membrane protein expression in tumor associated microvesicles can effectively discriminated PDAC cases from benign pancreatic diseases and healthy donors.